Title | Heart failure after allogeneic hematopoietic stem cell transplantation |
Authors | Mo, Xiao-Dong Xu, Lan-Ping Liu, Dai-Hong Zhang, Xiao-Hui Chen, Huan Chen, Yu-Hong Han, Wei Wang, Yu Wang, Feng-Rong Wang, Jing-Zhi Zhao, Ting Yan, Chen-Hua Sun, Yu-Qian Liu, Kai-Yan Huang, Xiao-Jun |
Affiliation | Peking Univ, Peoples Hosp, Beijing Key Lab Hematopoit Stem Cell Transplantat, Beijing 100044, Peoples R China. Inst Hematol, Beijing Key Lab Hematopoit Stem Cell Transplantat, Beijing 100044, Peoples R China. |
Keywords | Heart failure Allogeneic hematopoietic stem Transplant-related complication BONE-MARROW-TRANSPLANTATION HIGH-DOSE CYCLOPHOSPHAMIDE VERSUS-HOST-DISEASE CARDIAC COMPLICATIONS CHILDHOOD-CANCER PREDICTIVE-VALUE ONCOLOGY-GROUP ACUTE GVHD CARDIOTOXICITY THERAPY |
Issue Date | 2013 |
Publisher | international journal of cardiology |
Citation | INTERNATIONAL JOURNAL OF CARDIOLOGY.2013,167,(6),2502-2506. |
Abstract | Background: Heart failure (HF) occurring after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is rare but severe. We examine the role of pre-HSCT therapeutic exposures, conditioning regimens, pre-HSCT comorbidities, severe transplant-related complications, and post-HSCT cardiovascular risk factors in the development of heart failure after allo-HSCT. Methods: A nested case-control study was designed. Cases with HF and controls matched for age, year of allo-HSCT, and length of follow-up were identified from a cohort of 2455 patients who underwent allo-HSCT between 2000 and 2011 for hematologic malignancies. Results: Forty-two patients suffered from HF; mean age at presentation was 35 years (+/- 14 years) and mean time to presentation was 5 months (+/- 9 months) post-HSCT. The number of pre-HSCT cycles of chemotherapy was significantly greater (7 vs. 5 courses, P=0.023). Cases were significantly more likely to have severe acute GVHD (>= grade III), hemorrhagic cystitis (>= grade 2), and multiple severe transplant-related complications compared with controls (42.9% vs. 20.4%, P=0.008). Multivariate analysis revealed that pre-HSCT cycles of chemotherapy of >= 5 courses (OR=3.5, P=0.003) and two or more severe transplant-related complications (OR=3.6, P=0.003) were independently associated with HF. Conclusions: These results identify the individuals who are at higher risk of developing HF after allo-HSCT. We should pay more attention to these patients and more active management would be reasonable. (C) 2012 Elsevier Ireland Ltd. All rights reserved. |
URI | http://hdl.handle.net/20.500.11897/191204 |
ISSN | 0167-5273 |
DOI | 10.1016/j.ijcard.2012.06.021 |
Indexed | SCI(E) PubMed |
Appears in Collections: | 人民医院 |